8:30 am Chair’s Opening Remarks

8:45 am Reserved for Expertise Partner

  • Josh Hoerner General Manager & Vice President - Research & Development Noramco, Purisys

9:00 am Panel Discussion Reserved for Expertise Partner

9:30 am Cannabis 3.0 – Pharmaceutical or Botanical?

Synopsis

  • Understand how the marijuana plant has been used as a complex botanical medicine for millennia
  • Examine Emyria’s large real-world clinical e-registry and how it provides longitudinal efficacy and safety data on GMP plant-derived oral cannabinoids informing clinical indications and dosing
  • Explore Emyria’s development of consistent, stable, highly bioavailable, pure quality, bioidentical cannabinoids for specific indications for pharmaceutical registration

10:00 am Morning Break & Speed Networking

Discovering the Next Generation of Novel Cannabinoid Pharmaceuticals

Chairman: Brian Murphy, Former Chief Executive Officer, Emerald Biosciences

11:00 am Utilizing Rigorous Chemistry Principles to Gain a Clear View of the Potential of THC & CBD

  • Anthony Almada Founder, President & Chief Scientific Officer, IMAGINutrition, Inc.

Synopsis

  • What are the vital toxicological and PD/PK unknowns that are inhibiting true progress in CDPs?
  • How can we go about filling in the gaps as an entire field?

11:30 am AI/ML-Accelerated Plant-Based Drug Discovery

Synopsis

  • Discover and evaluate plant-inspired therapeutic mixtures using in-silico tools (artificial intelligence/ machine learning/data analytics)
  • Case Study: Examine immune system modulating mixtures designed to treat Cytokine Release Syndrome
  • Explore preclinical validation of in-silico drug candidates for Cytokine Release Syndrome (CRS)

Meeting the Growing Need for High-Quality Pure Cannabinoids & Managing Logistical Challenges

Chairman: Mike Woudenberg, Senior Vice President, Chemistry, Manufacturing & Controls, InMed Pharmaceuticals

11:00 am Advances in Biosynthetic Cannabinoid Production of Rare Cannabinoids

  • Eric Hsu Vice President - Preclinical, Research & Development, InMed Pharmaceuticals Ltd
  • Chris Meiering Vice President Commercialization, Inmed Pharmaceuticals

Synopsis

  • Get an end-to-end view of how Inmed select a cannabinoid to pursue and the process that follows
  • Discuss the upcoming cannabinoids the Inmed/ Baymedica team are looking to pursue

11:30 am Biosynthesis of Cannabinoids

  • Neda Mashadi Post-Doctoral Research Fellow, University of Windsor

Synopsis

  • Discuss the creation, characterization, and stress-testing of a robust cannabidiol nanoemulsion created using GRAS (generally recognized as safe) ingredients
  • Examine how in a follow-up study, the energy-intensive homogenization step associated with nanoemulsion formation, which requires a specialized instrument leading to higher cost, will be replaced by a solventassisted homogenization protocol, producing a stable emulsion that can then be freeze-dried or spray-dried to form water-redispersible powder formulations
  • Explore the design, synthesis, and nanoformulationrelated applications of novel polyphenol-protein conjugate emulsifiers with intrinsic antioxidant properties

12:00 pm Lunch Break

Preclinical Development

1:00 pm Challenges & Successes in Moving Promising Preclinical Cannabinoid Drug Candidates to the Clinic

Synopsis

  • Identify robust pre-clinical drug targets for cannabinoid drug development
  • Evaluate pre- and post-COVID cannabinoid drug development challenges: spotlight on systemic inflammatory disease
  • Examine future development of cannabinoid drug products for expanded disease indications

1:30 pm Effective Early Stage Research

  • Hunter Land Vice President Translational Research & Board Member, Alterola Biotech Inc.

Synopsis

  • Conducting preliminary preclinical development
  • Designing early phase/proof of concept clinical to maximize your chance of achieving success

2:00 pm Pharmaceutical Cannabinoids: A Company Update

  • Arnold Lippa Exec. Chairman, Chief Executive Officer and Chief Scientific Officer, RespireRx Pharmaceuticals Inc

Synopsis

  • Examine re-purposing of dronabinol for the treatment of obstructive sleep apnea (OSA) and other indications
  • Explore completion of two successful Phase 2 clinical trials in OSA
  • Develop lipid nanoparticle formulation to overcome current dronabinol limitations

Phytocannabinoid Production

1:00 pm Panel Discussion: Meeting the Growing Demand for Cannabinoids for Research, Therapeutics & Consumer Products

  • Chris Meiering Vice President Commercialization, Inmed Pharmaceuticals
  • Eric Hsu Vice President - Preclinical, Research & Development, InMed Pharmaceuticals Ltd
  • Neda Mashadi Post-Doctoral Research Fellow, University of Windsor

Synopsis

  • Identify new learnings that have been discovered in the discussion around phytocannabinoids vs synthetic
  • Has the promise of biosynthesis been overestimated?
  • Coach before the horse: What is the rationale in trying to explore new cannabinoids when many questions still remain about the therapeutic action of CBD and THC?

1:30 pm SuperFluids™ Manufacturing of Pharmaceutical- Grade Natural Cannabinoids

Synopsis

  • Examine core SuperFluids Extraction and chromatographic purification technologies
  • Discuss downstream purification and crystallization
  • Evaluate chemistry, manufacturing and controls, analytical characterization and cGMP documentation

2:00 pm Building an Ophthalmic Pipeline of Cannabinoid Derivative

  • Karam Takhar Vice President, Corporate Development, Skye Bioscience

Synopsis

  • Optimize drug delivery of cannabinoids, starting with occular
  • Examine how these learnings can be taken into new therapeutic areas

2:30 pm Afternoon Break

3:00 pm Evolving Federal Cannabis Policy

  • Kay Doyle Director, Policy & Public Affairs, Greenwich Biosciences

Synopsis

  • Federal lawmakers are introducing bills designing the framework for future legalization, such as the Cannabis Administration and Opportunity Act and State
  • Reform Act. Prepare for the potential implications on cannabinoid drug development
  • What can we do to further inform lawmakers about the need to incentivize the drug development?

3:30 pm Misconceptions Around the 505(b) Pathway

4:00 pm Updates on UK Medical Cannabis Regulation

Synopsis

  • What is understood about the FSA’s recently published list of CBD products?
  • How does this impact the wider landscape of medical cannabis and cannabinoid pharmaceutical products?

4:30 pm Chair’s Closing Remarks

4:45 pm End of Day One